登录查看更多内容

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

Eupraxia Pharmaceuticals Inc.

Developing Precision Therapies

发布日期: 2024年11月7日

VICTORIA, BC, Nov. 7, 2024 -?Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere? technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the third quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise.

To view the press release, please click here:

https://eupraxiapharma.com/news/news-details/2024/Eupraxia-Pharmaceuticals-Reports-Third-Quarter-2024-Financial-Results/default.aspx

要查看或添加评论，请登录

Eupraxia Pharmaceuticals Inc.的更多文章

2025年2月27日

Eupraxia Will Be At Canadian Digestive Diseases Week

The team invites you to visit the Company's booth (CD7) between February 28th and March 2nd, 2025, in Quebec City…
2025年2月19日

We are hiring a Vice-President, Business Development

Vice-President, Business Development About Us: Eupraxia is a clinical-stage biotechnology company focused on developing…
2025年2月18日

Eupraxia Pharmaceuticals Announces CFO Succession

Victoria, B.C.
2025年1月31日

We are hiring a Director, Business Operations

Director, Business Operations About Us: Eupraxia is a clinical-stage biotechnology company focused on developing…
2025年1月24日

We are hiring a Director, Medical Affairs

Director, Medical Affairs About Us: Eupraxia is a clinical-stage biotechnology company focused on developing locally…
2025年1月23日

We are hiring an IT Operations Manager

IT Operations Manager About Us: Eupraxia is a clinical-stage biotechnology company focused on developing locally…
2024年11月20日

Eupraxia's DiffuSphere? Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

VICTORIA, BC, Nov. 20, 2024 - Eupraxia Pharmaceuticals Inc.
2024年11月14日

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

VICTORIA, BC, Nov. 14, 2024 - Eupraxia Pharmaceuticals Inc.
2024年11月13日

Eupraxia CEO Dr. James Helliwell to Participate in Webinar Event

VICTORIA, BC, Nov. 13, 2024 - Eupraxia Pharmaceuticals Inc.
2024年11月13日

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Victoria, B.C.

See all articles

社区洞察

Analytical Methods Development

How do you handle method transfer and comparability studies?
Entrepreneurship

What are the most effective ways to manage innovation in a biopharmaceutical business?
Biotechnology

Your client doubts the quality of your biopharmaceutical product. How will you address their concerns?
Financial Management

How do transfer pricing methods impact pharmaceutical companies?
Bioengineering

How can you ensure the safety and effectiveness of combination products during design review and approval?
GMP

What are the most common pitfalls and mistakes to avoid in drug product specification development?
Management Consulting

How can you help a pharmaceutical company rapidly develop new products?
GMP

How do you keep up with the latest trends and innovations in drug product specification development?
Technical Analysis

How can you use decision trees to evaluate a capital investment in pharmaceuticals?
GMP

How do you find GMP guidance?

其他会员也浏览了

Eupraxia Pharmaceuticals Reports Third Quarter 2023 Financial Results

Eupraxia Pharmaceuticals Inc. 1 年
Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference

Eupraxia Pharmaceuticals Inc. 11 个月
Eupraxia Pharmaceuticals Reports First Quarter 2023 Financial Results

Eupraxia Pharmaceuticals Inc. 1 年
Eupraxia Pharmaceuticals Completes C$14.7 million Overnight Marketed Offering

Eupraxia Pharmaceuticals Inc. 2 年
Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024

Eupraxia Pharmaceuticals Inc. 5 个月
Eupraxia Pharmaceuticals Strengthens Senior Management Team

Eupraxia Pharmaceuticals Inc. 5 个月
Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Eupraxia Pharmaceuticals Inc. 1 年
Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference

Eupraxia Pharmaceuticals Inc. 1 年
Eupraxia Pharmaceuticals Announces Expansion of Intellectual Property For EP-104IAR

Eupraxia Pharmaceuticals Inc. 2 年
Incannex Healthcare Limited

Cannabis LED Grow Light Factory and Solution Provider 2 年

Eupraxia Pharmaceuticals Inc.的更多文章

Eupraxia Will Be At Canadian Digestive Diseases Week

We are hiring a Vice-President, Business Development

Eupraxia Pharmaceuticals Announces CFO Succession

We are hiring a Director, Business Operations

We are hiring a Director, Medical Affairs

We are hiring an IT Operations Manager

Eupraxia's DiffuSphere? Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

Eupraxia CEO Dr. James Helliwell to Participate in Webinar Event

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

社区洞察

其他会员也浏览了

Eupraxia Pharmaceuticals Reports Third Quarter 2023 Financial Results

Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference

Eupraxia Pharmaceuticals Reports First Quarter 2023 Financial Results

Eupraxia Pharmaceuticals Completes C$14.7 million Overnight Marketed Offering

Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024

Eupraxia Pharmaceuticals Strengthens Senior Management Team

Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference

Eupraxia Pharmaceuticals Announces Expansion of Intellectual Property For EP-104IAR

Incannex Healthcare Limited